- Type 2 diabetes
Dr. Bruno Guigas is a 42 year-old molecular biologist with a broad expertise in the pathophysiology of metabolic disorders. Established in The Netherlands for almost a decade with a tenure-track position at the department of Parasitology, he’s currently heading a group of ~5 people. During the last years, he has driven several research projects aiming to identify novel therapeutic strategies for obesity and type 2 diabetes, using both in vitro and in vivo approaches in rodent models or humans. More recently, he launched a novel research line within the emerging field of immunometabolism aiming to identify new druggable molecules and/or molecular targets involved in immune-dependent regulation of insulin sensitivity. He’s is also actively involved in several international collaborations on multidisciplinary projects in the field of obesity and type 2 diabetes. Overall, these various research activities have resulted in >80 peer-reviewed publications (h-index:36), including some in high-impact journals. As a recognized expert, Dr. Guigas is also serving as external reviewer for multiple journals (>100 publications) and funding agencies (>30 grants). He is also a member of the Scientific Advisory Board of Valbiotis, a French biotech developing innovative plant-derived molecules for preventing metabolic syndrome.
Guigas' group is mainly focused on studying the molecular mechanisms underlying the immune-mediated regulation of metabolic homeostasis by parasites and their molecules (http://help-t2d.nl/), using both in vitro and in vivo approaches in various rodent models or in humans. This original research line is aimed to identify new molecules and/or potential novel molecular targets involved in tissue-specific regulation of glucose/lipid metabolism and insulin sensitivity that can ultimately lead to future therapeutic opportunities for the treatment of metabolic disorders and type 2 diabetes.
Current main research fundings
• Grant from ZonMW: ‘Helminth-derived glycoproteins and insulin sensitivity: from immunomodulatory properties to direct regulation of metabolic tissues.’
• Grant from DiabetesFonds/ZonMW: ‘Role of protein glycosylation in macrophage-adipocyte crosstalk during obesity’
Foretz M*, Guigas B*, Viollet B. Metformin and type 2 diabetes: moving towards understanding the glucoregulatory mechanisms. (2019). Nature Reviews Endocrinology, in press.
Thomas A, Belaïdi E, Moulin S, Horman S, van der Zon GC, Viollet B, Levy P, Bertrand L, Pepin JL, Godin-Ribuot D, Guigas B. Chronic intermittent hypoxia impairs insulin sensitivity but improves whole-body glucose tolerance by activating skeletal muscle AMPK. (2017). Diabetes, 66(12):2942-2951.
Guigas B and Molofsky AB. A worm of one's own: how helminths modulate host adipose tissue function and metabolism. (2015). Trends in Parasitology, 31(9):435-41.
Hussaarts L, Garcia-Tardon N, van Beek L, Heemskerk MM, Haeberlein S, van der Zon GC, Ozir-Fazalalikhan A, Berbee JF, Willems van Dijk K, van Harmelen V, Yazdanbakhsh M, Guigas B. Chronic helminth infection promotes adipose tissue M2 macrophages and improves insulin sensitivity in obese mice. (2015). FASEB J, 29(7):3027-39.
Geerling JJ, Boon MR, van der Zon GC, van den Berg SAA, van den Hoek AM, Lombes M, Princen HM, Havekes LM, Rensen PCN, Guigas B. Metformin reduces plasma cholesterol and triglyceride levels by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. (2014). Diabetes, 63(3):880-91.
Wijngaarden MA, van der Zon GC, Willems van Dijk K, Pijl H, Guigas B. Effects of prolonged fasting on AMP-activated protein kinase signaling, metabolic gene expression and mitochondrial content in skeletal muscle from lean and obese individuals. (2013). AJP-Endocrinology & Metabolism, 304(9):E1012-21.
Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal EM, Hue L, Viollet B, Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. (2011). Diabetologia, 54(12):3101-10.
All publications can be found at Google Scholar
Leids Universitair Medisch Centrum
2333 ZA Leiden
Tel: +31 71 526 1328
2300 RC Leiden